SEC File Number:
0-33473
CUSIP Number:
92823V 20 2
================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
(Check One): |X| Form 10-KSB |_| Form 20-F |_| Form 11-K |_| Form 10-Q
|_| Form 1OD |_| Form N-SAR |_| Form N-CSR
For Period Ended: April 30, 2006
|_| Transition Report on Form 10-K
|_| Transition Report on Form 20-F
|_| Transition Report on Form 11-K
|_| Transition Report on Form 10-Q
|_| Transition Report on Form N-SAR
For the Transition Period Ended:______________________________
- --------------------------------------------------------------------------------
Nothing in this form shall be construed to imply that the Commission has
verified any information contained herein.
- --------------------------------------------------------------------------------
If the notification relates to a portion of the filing checked above, identify
the items(s) to which the notification relates:
- --------------------------------------------------------------------------------
================================================================================
PART I -- REGISTRANT INFORMATION
Viridax Corporation
- --------------------------------------------------------------------------------
Full Name of Registrant
I & E Tropicals, Inc.
- --------------------------------------------------------------------------------
Former Name if Applicable
270 NW 3rd Court
- --------------------------------------------------------------------------------
Address of Principal Executive Office (Street and Number)
Boca Raton, Florida 33432
- --------------------------------------------------------------------------------
City, State and Zip Code
PART II
RULE 12b-25 (b) AND (c)
If the subject report could not be filed without unreasonable effort or
expense and the Registrant seeks relief pursuant to Rule 12b-25(b), the
following should be completed. (Check box if appropriate)
(a) The reasons described in reasonable detail in Part III of this form
could not be eliminated without unreasonable effort or expense;
(b) The subject annual report, semi-annual report, transition report on
Form 1O-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or
portion thereof, will be filed on or before the fifteenth calendar
|X| day following the prescribed due date; or the subject quarterly
report or transition report on Form 10-Q or subject distribution
report on Form 10-D, or portion thereof, will be filed on or before
the fifth calendar day following the prescribed due date; and
(c) The accountant's statement or other exhibit required by Rule
12b-25(c) has been attached if applicable.
PART III
NARRATIVE
At the request of our auditor, the Company has retained the the services
of an independent firm to perform a valuation to determine if there is
impairment as defined in SFAS 142 for certain bacteriophage-based products owned
by the Company as of the end of the fiscal year ended April 30, 2006. The
conduct of this valuation has required investigations and procedures far more
extensive than originally contemplated. Accordingly, the Company requires
additional time for this valuation report to be completed and included within
Form 10-KSB.
PART IV
OTITER INFORMATION
(1) Name and telephone number of person to contact in regard to this
notification.
Ledyard H. Dewees 561 368-1427
- --------------------------------------------------------------------------------
(Name) (Area Code) (Telephone Number)
(2) Have all other periodic reports required under Section 13 or 15(d) of
the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act
of 1940 during the preceding 12 months or for such shorter period that the
Registrant was required to file such report(s) been filed? If the answer is no,
identify report(s).
|X| Yes |_| No
(3) Is it anticipated that any significant change in results of
operations from the corresponding period for the last fiscal year will be
reflected by the earnings statements to be included in the subject report or
portion thereof?
|_| Yes |X| No
If so: attach an explanation of the anticipated change, both narratively
and quantitatively, and, if appropriate, state the reasons why a reasonable
estimate of the results cannot be made.
Viridax Corporation
- --------------------------------------------------------------------------------
(Name of Registrant as specified in charter)
has caused this notification to be signed on its behalf by the undersigned
thereunto duly authorized.
Date: July 18, 2006 By: /s/ Richard C. Honour
------------------------
Name: Richard C. Honour
Title: President
ATTENTION
Intentional misstatements or omissions of fact constitute Federal criminal
violations (see 18 U.S.C. 1001).